Targeting cell recycling processes in certain cancers
Mechanistic dissection and inhibitor targeting of autophagy in RAS driven cancers
['FUNDING_R37'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10843305
This study is looking at how a process that helps cells clean up their mess can affect the growth of pancreatic cancer caused by a specific gene mutation, and it’s testing whether using a drug that slows down this cleaning process can make other cancer treatments work better for patients with this type of cancer.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10843305 on ClinicalTrials.gov |
What this research studies
This research investigates how a cellular process called autophagy, which helps cells recycle and clear damaged components, is crucial for the growth of pancreatic cancer driven by mutations in the KRAS gene. The study aims to evaluate the effectiveness of combining autophagy inhibitors, like hydroxychloroquine, with other cancer treatments that target the KRAS pathway. By understanding the relationship between these treatments and autophagy, the researchers hope to enhance the effectiveness of existing therapies for patients with this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma that has KRAS mutations.
Not a fit: Patients with pancreatic cancer that does not have KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KRAS-mutant pancreatic cancer.
How similar studies have performed: Other research has shown promising results with similar approaches, indicating potential for significant advancements in treatment.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRYANT, KIRSTEN L — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: BRYANT, KIRSTEN L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.